维持性血液透析患者的药物负担与不良心血管事件及死亡风险:全国性队列研究
该研究分析29690例维持性血液透析患者,发现药物负担越高,主要不良心脑血管事件(MACCE)风险越高。与最低四分位相比,最高四分位调整后风险比为1.27,每增加一种药物风险增加1.03倍。药物负担可作为临床风险指标。
要点
- 药物负担越高,MACCE发生风险逐步升高。
- 最高四分位药物负担者MACCE风险是最低四分位的1.27倍。
- 每增加一种常规口服药物,主要结局风险增加3%。
核心结论
- 高药物负担与维持性血液透析患者不良心血管结局及全因死亡风险独立相关。
研究设计与样本
- 全国性队列研究,纳入29690例接受维持性血液透析并参与健康保险审查评价院定期血液透析质量评估的患者。
主要发现
- 随访146749人年(中位6.0年),17573例(59.2%)发生MACCE。
- Q1至Q4的MACCE发生率分别为每1000人年84.7、107.2、130.2和168.9例。
- 与最低四分位相比,第二、第三和最高四分位的调整风险比(95%CI)分别为1.05(1.00-1.10)、1.12(1.07-1.17)和1.27(1.21-1.33)。
- 连续模型中,每增加一种药物,主要结局风险增加1.03倍(95%CI 1.03-1.04)。
临床怎么用
- 药物负担可作为维持性血液透析患者不良心血管事件和全因死亡的临床风险指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: A higher medication burden was associated with a higher risk of adverse events in patients receiving maintenance hemodialysis. Medication burden can serve as a clinically relevant risk indicator for cardiovascular events and all-cause death in patients on maintenance hemodialysis. BACKGROUND: A high medication burden is associated with adverse outcomes. Although patients with ESKD have a substantial medication burden, the relationship between the number of medications in use and clinical outcomes in these patients remains unclear. Hence, this study aimed to investigate the prognostic implications of medication burden regarding adverse outcomes in patients with ESKD on maintenance hemodialysis. METHODS: We analyzed 29,690 patients receiving maintenance hemodialysis who participated in the Periodic Hemodialysis Quality Assessment conducted by the Health Insurance Review and Assessment Service. The exposure of interest was the number of routinely prescribed oral medications. The main outcome was a composite of nonfatal cardiovascular events (nonfatal myocardial infarction, coronary revascularization, nonfatal stroke, or hospitalization for heart failure) or all-cause death (major adverse cardiac and cerebrovascular events [MACCEs]). The secondary outcomes were the individual components of the primary outcome. RESULTS: During a follow-up period of 146,749 person-years (median, 6.0 years), MACCEs occurred in 17,573 patients (59.2%). Higher medication burden was associated with progressively higher incidence of MACCEs (84.7, 107.2, 130.2, and 168.9 events per 1000 person-years in Q1–Q4, respectively). In a multivariable Cox proportional hazard model, the adjusted hazard ratios (95% confidence intervals) for the second, third, and highest quartiles were 1.05 (1.00 to 1.10), 1.12 (1.07 to 1.17), and 1.27 (1.21 to 1.33), respectively, compared with the lowest quartile. In continuous modeling, each increase in the number of medication was associated with a 1.03-fold (95% confidence interval, 1.03 to 1.04) higher risk of the primary outcome. CONCLUSION: A high medication burden was independently associated with higher risk of adverse cardiovascular outcomes and all-cause death in patients receiving maintenance hemodialysis. These findings suggest that a high medication burden could be a useful indicator of adverse clinical outcomes in patients undergoing hemodialysis.
引用
- Park CH, Ko YE, Heo GY, et al. Medication Burden and Adverse Cardiovascular Events and Death in Patients Treated with Maintenance Hemodialysis: A Nationwide Cohort Study. Clin J Am Soc Nephrol. 2024. PMID: 39729594. doi:10.2215/CJN.0000000000000570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。